Mizuho Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $39
Mizuho Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $39
瑞穗維持對EyePoint製藥的買入，將目標股價上調至39美元
Mizuho analyst Graig Suvannavejh maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and raises the price target from $30 to $39.
瑞穗分析師格雷格·蘇萬納維耶維持EyePoint Pharmicals（納斯達克股票代碼：EYPT）的買入並將目標股價從30美元上調至39美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。